Sandoz (SIX:SDZ / OTCQX:SDZNY), the global leader in affordable medicines, will host its 2026 capital markets day on Tuesday, 8 September, at the London Stock Exchange, with a live webcast from 13:30 to 17:00 UK time. The event, themed 'Maximising Sandoz Value in Its Golden Decade for Biosimilars,' will provide investors and analysts with insights into the company's strategy and growth prospects. In-person attendance is by invitation only on a first-come, first-served basis, and details for accessing the live webcast are available here.
Additionally, Sandoz plans an investor and analyst site visit in Slovenia from 9-10 November, offering a deeper look into its new biosimilars development and supply-chain hub. This visit, also by invitation only, will not be webcasted. These events underscore Sandoz's commitment to transparency and engagement with the financial community as it capitalizes on what it calls a 'golden decade' for biosimilars, driven by patent expiries of major biologic drugs and increasing global demand for affordable alternatives.
With a portfolio of approximately 1,300 medicines, Sandoz generated net sales of USD 11.1 billion in 2025. The company celebrates 20 years of pioneering biosimilars in 2026, alongside 80 years of antibiotics manufacturing and 140 years of heritage. Sandoz's leadership in biosimilars positions it to address rising healthcare costs and expand patient access, a mission that resonates with policymakers and payers worldwide. The capital markets day is expected to detail how Sandoz intends to leverage its scale, R&D pipeline, and manufacturing capabilities to sustain growth and create shareholder value.
The forward-looking statements in the announcement caution that actual results may differ due to risks such as global economic conditions, exchange rates, and competitive activities. Nonetheless, Sandoz remains focused on its purpose: pioneering access for patients. Over 20,000 colleagues of 100 nationalities work together to reach more than one billion patients, generating substantial healthcare savings and social impact. The upcoming events provide a platform for Sandoz to articulate its vision for the next decade and reinforce its position as a leader in the biosimilars market.
